UBS Group
TCRX icon

UBS Group’s TScan Therapeutics TCRX Stock Holding History

UBS Group’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67.5K Buy
68,873
+36,389
+112% +$38.8K ﹤0.01% 7408
2026
Q1 		$32.8K Sell
32,484
-22,714
-41% -$24.3K ﹤0.01% 7632
2025
Q4 		$55.2K Buy
55,198
+44,125
+398% +$63.9K ﹤0.01% 7172
2025
Q3 		$20.2K Sell
11,073
-389,328
-97% -$690K ﹤0.01% 8146
2025
Q2 		$581K Buy
400,401
+276,960
+224% +$400K ﹤0.01% 5883
2025
Q1 		$170K Buy
123,441
+31,581
+34% +$68.3K ﹤0.01% 6651
2024
Q4 		$279K Buy
91,860
+72,516
+375% +$329K ﹤0.01% 6238
2024
Q3 		$96.3K Buy
19,344
+6,699
+53% +$40.4K ﹤0.01% 6399
2024
Q2 		$74K Buy
12,645
+10,744
+565% +$84.6K ﹤0.01% 6386
2024
Q1 		$15.1K Buy
1,901
+477
+33% +$3K ﹤0.01% 7046
2023
Q4 		$8.3K Buy
1,424
+309
+28% +$1.41K ﹤0.01% 7567
2023
Q3 		$2.85K Buy
1,115
+15
+1% +$35 ﹤0.01% 7637
2023
Q2 		$2.75K Sell
1,100
-2,140
-66% -$5.74K ﹤0.01% 7704
2023
Q1 		$6.8K Buy
3,240
+2,240
+224% +$5.32K ﹤0.01% 7880
2022
Q4 		$1.55K Sell
1,000
-2,441
-71% -$5.99K ﹤0.01% 9843
2022
Q3 		$11K Buy
3,441
+2,293
+200% +$7.51K ﹤0.01% 8329
2022
Q2 		$4K Buy
+1,148
New +$3.14K ﹤0.01% 9129
2022
Q1 		– Sell
-811
Closed -$4K – 10884
2021
Q4 		$4K Sell
811
-135
-14% -$975 ﹤0.01% 9550
2021
Q3 		$8K Buy
+946
New +$8.77K ﹤0.01% 8227

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

UBS Group's TCRX Position: Q2 2026 in Review

UBS Group increased its TScan Therapeutics (TCRX) stake by 112% in Q2 2026, buying an estimated $38.8K and bringing the position to 68,873 shares worth $67.5K. The position accounts for ﹤0.01% of the portfolio, ranked #7408.

UBS Group first reported a position in TCRX in Q3 2021 and has held it in 19 quarters since. The position peaked at $581K in Q2 2025. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • UBS Group held 68,873 shares of TScan Therapeutics worth $67.5K as of Q2 2026.
  • UBS Group bought 36,389 TScan Therapeutics shares in Q2 2026, an estimated $38.8K.
  • TScan Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7408 holding.
  • UBS Group first reported a position in TScan Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • UBS Group's TScan Therapeutics position peaked at $581K in Q2 2025.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.